GSK and Helix struck a multi‑year collaboration giving GSK access to curated clinico‑genomic cohorts in Helix’s GenoSphere database to support precision‑medicine drug R&D. The arrangement includes whole-exome sequencing, longitudinal clinical data, and linked third‑party claims, with more than 300,000 consented records available for cohort discovery across autoimmune, cardiometabolic and renal indications. GSK said it will use the dataset to integrate genetics and genomics into decision-making across discovery and development. Helix emphasized that cohorts are recontactable and include specialized patient subsets to accelerate translational research. The deal exemplifies big-pharma moves to assemble longitudinal, consented genomic datasets to improve target selection, biomarker strategies and trial enrichment—particularly where human genetic evidence can de‑risk programs.